Personalizing Medicine today!

Would you like an information package?

Sign up to receive E-mail updates on advances in pharmacogenetics.

Pharmacogenetic testing is the alternative to “one size fits all” and “trial and error” prescribing. Knowledge of patient drug metabolizing gene variants, found in more than half of patients, can help determine the appropriateness and dosage of many of the most commonly prescribed drugs including:

  • SSRI & TCA antidepressants
  • opioid pain medications
  • beta blockers
  • Type I antiarrhythmics
  • warfarin

Genelex currently offers straightforward genetic tests that reliably identify and classify CYP2D6, CYP2C9,CYP2C19, CYP1A2, and NAT2 into their slow, normal, and ultra-fast metabolizing forms.

Physician Benefits

  • Maximize treatment success by individualizing patient treatments to match their unique genetic make-up.
  • Opportunity to build your practice.
  • Minimize liability by reducing “trial and error” prescribing.
  • Keep current with the latest advances in genetic science.

Patient Benefits

  • Increased effectiveness of medication and nutritional supplements.
  • Optimized safety of prescription regimens.
  • Improved health.
  • Proactive in treatment choices.
 

Pharmacogenetic Effect of
Cytochrome Genotypes

A. PM poor metabolizer, absent or greatly reduced ability to clear or activate drugs.
B. IM intermediate metabolizer. Heterozygotes for normal and reduced activity genes.
C. EM extensive metabolizer. The norm.
D. UM Ultra Metabolizer. Greatly increased activity accelerating clearance or activation

Population Frequency of Cytochrome p450 (CYP) genotypes

GenePMIMEMUM
CYP2D610%35%48%7%
CYP2C94%38%58% N/A
CYP2C19 3-21%N/A79-97%N/A

Currently Available Tests

Individualized Patient Reports based on patient drug, herbal and diet regimens

Ordering Tests

Currently Available Tests
CYP2D6 (cytochrome P450 2D6) is the best studied of the DMEs and acts on one-fourth of all prescription drugs, including the selective serotonin reuptake inhibitors (SSRI), tricylic antidepressants (TCA), betablockers such as Inderal and the Type 1A antiarrhythmics. Approximately 10% of the population has a slow acting form of this enzyme and 7% a super-fast acting form. Thirty-five percent are carriers of a non-functional 2D6 allele, especially elevating the risk of ADRs when these individuals are taking multiple drugs. Drugs that CYP2D6 metabolizes include Prozac, Zoloft, Paxil, Effexor, hydrocodone , amitriptyline, Claritin, cyclobenzaprine, Haldol, metoprolol, Rythmol, Tagamet, tamoxifen, and the over-the-counter diphenylhydramine drugs, Allegra, Dytuss, and Tusstat. CYP2D6 is responsible for activating the pro-drug codeine into its active form and the drug is therefore inactive in CYP2D6 slow metabolizers.

CYP2C9 (cytochrome P450 2C9) is the primary route of metabolism for Coumadin (warfarin) and Dilantin (phenytoin). Approximately 10% of the population are carriers of at least one allele for the slow-metabolizing form of CYP2C9 and may be treatable with 50% of the dose at which normal metabolizers are treated. Other drugs metabolized by CYP2C9 include Amaryl, isoniazid, sulfa, ibuprofen, amitriptyline, Hyzaar, THC (tetrahydrocannabinol), naproxen, and Viagra.

CYP2C19 (cytochrome P450 2C19) is associated with the metabolism of carisoprodol, diazepam, Dilantin, and Prevacid.

CYP1A2 (cytochrome P450 1A2) is associated with the metabolism of amitriptyline, olanzapine, haloperidol, duloxetine, propranolol, theophylline, caffeine, diazepam, chlordiazepoxide, estrogens, tamoxifen, and cyclobenzaprine.

NAT2 (N-acetyltransferase 2) is a second-step DME that acts on isoniazid, procainamide, and Azulfidine. The frequency of the NAT2 “slow acetylator” in various worldwide populations ranges from 10% to more than 90%.

Individualized Patient Reports based on patient drug, herbal and diet regimens
DNA test reports can include patient specific information on potential drug drug interactions (DDIs) mediated by the tested polymorphic drug metabolizing enzymes, taking into account patient dietary, OTC and botanical medicines. Testing patients for drug metabolizing enzyme genotypes provides physicians with immediate insight into the vagaries of their patients’ drug processing ability, leading to improvements in efficacy and safety of prescribed treatments. This information will be especially valuable when potential drug-drug interactions (DDIs) are a possibility.

DNA Testing and personalized medicine
Genelex’s DNA Drug Reaction Tests for the highly polymorphic cytochromes, CYP2D6, CYP2C9, CYP1A2, and CYP2C19. These enzymes process half of the most commonly prescribed drugs, including many with narrow therapeutic indices and frequent participation in drug-drug interactions. (Drug Interaction Principles for Medical Practice, 2nd ed. APPI, 2003) Half of your patients have genetic variations in these genes that lead to altered or absent function resulting in elevated patient susceptibility to adverse drug reactions. Genotyping to avoid ADRs is a dependable tool to improve your practice today and begins your transition to the practice of tomorrow.


ADRs a serious medical problem

In 2000, Genelex began offering physicians an alternative to the “one size fits all” and “trial and error” prescribing of drugs. All too often, a serious adverse drug reaction (ADR) is the result. ADRs are not medical errors, but events that occur in spite of compliance with dosage recommendations. A 1998 meta-analysis of thirty-nine prospective studies in US hospitals estimated that 106,000 Americans die annually from ADRs. (JAMA, 279;1200 1998) Adverse drug events are also common (50 per 1000 person years) among ambulatory patients, particularly the elderly on multiple medications. The 38% of events classified as serious are also the most preventable. (JAMA, 289;1107 2003)

The role of genetics in drug metabolism
It is now clear that virtually every pathway of drug metabolism, transport and action is susceptible to genetic variation. It is estimated that 20 to 95 per cent of individual variability is genetic based. (NEJM 348;529 & 538 2003) Within the top 200 selling prescription drugs, 59% of the 27 most frequently cited in ADR studies are metabolized by at least one enzyme known to have gene variants that code for reduced or non-functional proteins. This compares with 7% of a random selection from the top 200 list. (JAMA, 286,2270 2001) Many other factors such as age, physiological functioning and concomitant disease are known and can be accounted for, leaving the genotype of the patient as a major unknown factor in the prescribing of medicines.